Document is current
Any future updates will be listed below
-
Authors
Mezzanotte-Sharpe, Jessica
Taylor, Brandie C.
Gonzalez-Ericsson, Paula I.
Sanchez, Violeta
Ocampo, Andres A.
Marshall, Jacey L.
Steele, Julia A.
Sanders, Melinda E.
Mayer, Ingrid A.
Balko, Justin M.
Kennedy, Laura C.
-
Funding
Funding for this research was provided by:
Vanderbilt Oncology Training Program T32 (2T32CA217834-07)
Stand Up to Cancer- Genentech Catalyst Research Grant (SU2C-AACR-CT09-17)
Stand Up to Cancer- Genentech Catalyst Research Grant (SU2C-AACR-CT09-17)
Stand Up to Cancer- Genentech Catalyst Research Grant (SU2C-AACR-CT09-17)
Stand Up to Cancer- Genentech Catalyst Research Grant (SU2C-AACR-CT09-17)
- License Information
-
More Information
Article History
Received: 20 December 2024
Accepted: 3 June 2025
First Online: 21 June 2025
Competing interests
: L.C.K. has served on advisory boards for Daiichi-Sankyo and AstraZeneca and has research funding from Puma Biotechnology. J.M.B. receives research support from Genentech/Roche and Incyte Corporation, has received advisory board payments from AstraZeneca, Eli Lilly, and Mallinckrodt and is an inventor on patents regarding immunotherapy targets and biomarkers in cancer. The other authors declare no potential conflicts of interest.
